Abstract

BackgroundAlzheimer’s disease (AD) is characterized by cognitive impairment that eventually develops into dementia. Amyloid-beta (Aβ) accumulation is a widely described hallmark in AD, and has been reported to cause olfactory dysfunction, a condition considered an early marker of the disease associated with injuries in the olfactory bulb (OB), the hippocampus (HIPP) and other odor-related cortexes. Adiponectin (APN) is an adipokine with neuroprotective effects. Studies have demonstrated that APN administration decreases Aβ neurotoxicity and Tau hyperphosphorylation in the HIPP, reducing cognitive impairment. However, there are no studies regarding the neuroprotective effects of APN in the olfactory dysfunction observed in the Aβ rat model. The aim of the present study is to determine whether the intracerebroventricular (i.c.v) administration of APN prevents the early olfactory dysfunction in an i.c.v Amyloid-beta1–42 (Aβ1–42) rat model. Hence, we evaluated olfactory function by using a battery of olfactory tests aimed to assess olfactory memory, discrimination and detection in the Aβ rat model treated with APN. In addition, we determined the number of cells expressing the neuronal nuclei (NeuN), as well as the number of microglial cells by using the ionized calcium-binding adapter molecule 1 (Iba-1) marker in the OB and, CA1, CA3, hilus and dentate gyrus (DG) in the HIPP. Finally, we determined Arginase-1 expression in both nuclei through Western blot.ResultsWe observed that the i.c.v injection of Aβ decreased olfactory function, which was prevented by the i.c.v administration of APN. In accordance with the olfactory impairment observed in i.c.v Aβ-treated rats, we observed a decrease in NeuN expressing cells in the glomerular layer of the OB, which was also prevented with the i.c.v APN. Furthermore, we observed an increase of Iba-1 cells in CA1, and DG in the HIPP of the Aβ rats, which was prevented by the APN treatment.ConclusionThe present study describes the olfactory impairment of Aβ treated rats and evidences the protective role that APN plays in the brain, by preventing the olfactory impairment induced by Aβ1–42. These results may lead to APN-based pharmacological therapies aimed to ameliorate AD neurotoxic effects.

Highlights

  • Alzheimer’s disease (AD) is characterized by cognitive impairment that eventually develops into dementia

  • We observed that Amyloid beta (Aβ) administration induced a significant increase in ionized calcium-binding adapter molecule 1 (Iba-1) positive cells in CA1, CA3 and dentate gyrus (DG)

  • We report a significant decrease in the amount of neuronal nuclei (NeuN) expressing cells in the glomerular layer of the olfactory bulb after Aβ administration, which probably correspond to periglomerular cells and the superficial axon cells [44]

Read more

Summary

Introduction

Alzheimer’s disease (AD) is characterized by cognitive impairment that eventually develops into dementia. Guzmán‐Ruiz et al BMC Neurosci (2021) 22:14 of the phosphorylated microtubule-associated protein tau (p-TAU) [1, 2] This results in neurodegeneration and cognitive impairment, including memory and olfactory dysfunction [3,4,5,6]. Accumulation of Aβ oligomers (AβO) in olfactory regions such as the olfactory epithelium, olfactory bulb (OB), anterior olfactory nucleus, piriform cortex, entorhinal cortex and hippocampus (HIPP) correlate with deficits in odor discrimination [6] Disorders such as obesity, metabolic syndrome and type 2 diabetes are risk factors for the development of neurodegenerative pathologies such as AD [11, 12]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.